Ullrich Graeven

Apr 27, 2024 | nature.com | Luca Fischer |Linmiao Jiang |Stephan Stilgenbauer |Ullrich Graeven |Jochen Greiner |Eric Durot | +3 more

AbstractThe therapy of relapsed or refractory (r/r) mantle cell lymphoma (MCL) patients remains a major clinical challenge to date. We conducted a randomized, open-label, parallel-group phase-III trial hypothesizing superior efficacy of rituximab, high-dose cytarabine and dexamethasone with bortezomib (R-HAD + B) versus without (R-HAD) in r/r MCL ineligible for or relapsed after autologous stem cell transplant (ASCT).

Dec 7, 2023 | nature.com | Elias K. Mai |Hans Salwender |Marc S. Raab |Katia Mancuso |Meral Beksac |Ullrich Graeven | +6 more

AbstractEarly morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for newly diagnosed multiple myeloma (NDMM), and developed/validated a predictive risk score. We evaluated 3700 transplant-eligible NDMM patients treated in 2005–2020 with novel agent-based triplet/quadruplet IT. Primary endpoints were severe infections, death, or a combination of both.